Болезнь Фабри с поражением почек с протеинурией и гипертрофической кардиомиопатией, ошибочно интерпретированная как хронический гломерулонефрит при пурпуре Шенлейна-Геноха


В.В. Фомин, А.А. Пулин, В.В. Рамеев, В.П. Седов, А.Д. Мешков, С.В. Рощупкина, В.В. Панасюк, Л.В. Козловская, Н.А. Мухин

ГОУ ВПО “Первый МГМУ имени И.М. Сеченова” Минздравсоцразвития РФ, Москва
Представлено описание пациента, страдающего болезнью Фабри с поражением почек, проявляющимся протеинурией, гипертрофической кардиомиопатией и кожными ангиокератомами, первоначально ошибочно интерпретированной как пурпура Шенлейна–Геноха, что повлекло за собой необоснованное применение глюкокортикостероидов и цитостатиков.

Литература


1. Breunig F., Wanner C. Update on Fabry disease: kidney involvement, renalprogression and enzyme replacement therapy. J Nephrol 2008; 21(1): 32–37.


2. Eng C.M., Fletcher J., Wilcox W.R. et al. Fabry disease: baseline medicalcharacteristics of a cohort of 1765 males and females in the Fabry Registry. JInherit Metab Dis 2007; 30(2): 184–192.


3. Eng C.M., Germain D.P., Banikazemi M., et al. Fabru disease: guidelines forthe evaluation and management of multi-organ system involvement. Genet Med2006; 8(9): 539–548.


4. Hoffmann B., Schwarz M., Mehta A., Keshav S; Fabry Outcome SurveyEuropean Investigators. Gastrointestinal symptoms in 342 patients with Fabrydisease: prevalence and response to enzyme replacement therapy. Clin.Gastroenterol. Hepatol. 2007; 5(12): 1447–1453.


5. MacDermot K.D., Holmes A., Miners A. Anderson-Fabry disease: clinicalmanifestations and impact of disease in a cohort of 98 hemizygous males. J.Med. Genet. 2001; 38: 769–775.


6. Banikazemi M., Ullman T., Desnick R.J. Gastrointestinal manifestations ofFabry disease: clinical response to enzyme replacement therapy. Mol. Genet.Metab. 2005; 85(4): 255–259.


7. Mohrenschlager M., Braun-Falco M., Ring J. et al. Fabry disease: recognitionand management of cutaneous manifestations. Am. J. Clin. Dermatol. 2003;4(3): 189–196.


8. Zarate Y., Hopkin R.J. Fabry’s disease. Lancet 2008; 372: 1427–1435.


9. Orteu C.H., Jansen T., Lidove O. et al. FOS Investigators. Fabry disease andthe skin: data from FOS, the Fabry outcome survey. Br. J. Dermatol. 2007;157(2): 331–337.


10. Fauchais A.L., Prey S., Outara B. et al. Angiokeratoma regression in a Fabrydisease after treatment with agalsidase-beta: clinical effectiveness marker? J.Eur. Acad. Dermatol. Venereol. 2010; 24(6): 737–738.


11. Cimaz R., Guillaume S., Hilz M.J. et al. Awareness of Fabry disease amongrheumatologists-current status and perspectives. Clin. Rheumatol. 2010 Apr 15.[Epub ahead of print].


12. Ries M., Moore D.F., Robinson C.J. et al. Quantative dysmorphology assessmentin Fabry disease. Genet. Med. 2006; 8: 96–101.


13. Oqvist B., Brenner B.M., Olivieira J.P. et al. Nephropathy in Fabry disease:the importance of early diagnosis and testing in high-risk populations. Nephrol.Dial. Transplant. 2009; 24: 1736–1743.


14. Schiffmann R., Warnock D.G.., Banikazemi M. et al. Fabry disease:progression of nepnropathy, and prevalence of cardiac and cerebrovascularevents before enzyme replacement therapy. Nephrol. Dial. Transplant. 2009;24: 2102–2111.


15. Ortiz A., Oliviero J.P., Waldek S. et al. Nephropathy in males and femaleswith Fabry disease: cross-sectional description of patients before treatmentwith enzyme replacement therapy. Nephrol. Dial. Transplant. 2008;23: 1600–1607.


16. Fogo A.B., Bostad L., Svarstad E. et al. Scoring system for renal pathology inFabry disease: report of the International Study Group of Fabry Nephropathy(ISFGN). Nephrol. Dial. Transplant. 2010; 25(7): 2168–2177.


17. Giannini E.H., Mehta A.B., Hilz M.J. et al. A validated disease severity scoringsystem for Fabry disease. Mol. Genet. Metab. 2010; 99: 283–290.


18. Nakao S., Kodama C., Takenaka T. et al. Fabry disease: detection ofundiagnosed hemodialysis patients and identification of a “renal variant”phenotype. Kidney Int. 2003; 64(3): 801–807.


19. Kotanko P., Kramar R., Devrnja D. et al. Results of a nationwide screening forAnderson-Fabry disease among dialysis patients. J. Am. Soc. Nephrol. 2004;15(5): 1323–1329.


20. Ichinose M., Nakayama M., Ohashi T. et al. Significance of screeningfor Fabry disease among male dialysis patients. Clin. Exp. Nephrol. 2005;9(3): 228–232.


21. Tanaka M., Ohashi T., Kobayashi M. et al. Identification of Fabryc s disease bythe screening of alpha-galactosidase A activity in male and female hemodialysispatients. Clin. Nephrol. 2005; 64(4): 281–287.


22. Lucke T., Hoppner W., Schmidt E. et al. Fabry disease: reduced activities ofrespiratory chain enzymes with decreased levels of energy-rich phosphates infibroblasts. Mol. Genet. Metab. 2004; 82: 93–97.


23. Shen J.S., Meng X.L., Moore D.F. et al. Globotriasylceramide inducesoxidative stress and up-regulates cell adhesion molecule expression in Fabrydisease endothelial cells. Mol. Genet. Metab. 2008; 95: 163–168.


24. Barbey F., Brakch N., Linhart A. et al. Cardiac and vascular hypertrophy inFabry disease: evidence for a new mechanism independent of blood pressureand glycosphingolipid deposition. Arterioscler. Thromb. Vasc. Biol. 2006;26: 839–844.


25. Linhart A., Kampmann C., Zamorano C.J. et al. Cardiac manifestations ofAnderson-Fabry disease: results from the international Fabry Outcome Survey.Eur. Heart J. 2007; 28: 1228–1235.


26. Monserrat L., Gimeno-Blanes J.R., Marin F. et al. Prevalence of fabry diseasein a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J. Am.Coll. Cardiol. 2007; 50(25): 2399–2403.


27. Nakao S., Takenata T., Maeda M. et al. An atypical variant of Fabry’sdisease in men with left venticular hypertrophy. N. Engl. J. Med. 1995;333: 288–293.


28. Sachdev B., Takenaka T., Maeda M. et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy.Circulation 2002; 105: 1407–1411.


29. Chimenti C., Pieroni M., Morgante E. et al. Prevalence of Fabry disease infemale patients with late-onset hypertrophic cadiomyopathy. Circulation. 2004;110: 1047–1053.


30. Ommen S.R., Nishimura R.A., Edwards W.D. Fabry disease: a mimic forobstructive hypertrophic cardiomyopathy? Heart 2003; 89: 929–930.


31. Weidemann F., Linhart A., Monserrat L. et al. Cardiac challenges in patientswith Fabry disease. Int. J. Cardiol. 2010; 141(1): 3–10.


32. Kampmann C., Linhart A., Baehner F. et al. Onset and progression of theAnderson-Fabry disease related cardiomyopathy. Int. J. Cardiol. 2008; 130(3):367–373.


33. Pierre-Louis B., Kumar A., Frishman W.H. Fabry disease. Cardiacmanifestations and therapeutic options. Cardiol. Rev. 2009; 17: 31–35.


34. Kouris N.T., Kontogianni D.D., Pavlou M.T. et al. Atrioventricular conductiondisturbances in a young patient with Fabry’s disease without other signs ofcardiac involvement. Int. J. Cardiol. 2005; 99(2): 327–328.


35. Efthimiou J., McLelland J., Betteridge D.J. Short PR intervalsand tachyarrhythmias in Fabry’s disease. Postgrad. Med. J. 1986;62(726): 285–287.


36. Hoigne P., Attenhofer Jost C.H., Duru F. et al. Simple criteria for differentiationof Fabry disease from amyloid heart disease and other causes of left ventricularhypertrophy. Int. J. Cardiol. 2006; 111(3): 413–422.


37. Joshi S.B., Ahmar W., Lee G., Aggarwal A. Fabry’s disease presentingas ventricular tachycardia and left ventricular “hypertrophy”. Eur. J.Echocardiogr. 2008; 9(5): 697–679.


38. Doi Y., Toda G., Yano K. Sisters with atypical Fabryc s disease with completeatrioventricular block. Heart. 2003; 89(1): e2.


39. Ikari Y., Kuwako K., Yamaguchi T. Fabryc s disease with completeatrioventricular block: histological evidence of involvement of the conductionsystem. Br. Heart J. 1992; 68(3): 323–325.


40. Ikari Y., Kuwako K., Yamaguchi T. Fabryc s disease with completeatrioventricular block: histological evidence of involvement of the conductionsystem. Br. Heart J. 1992; 68(3): 323–325.


41. Благова О.В., Заклязьминская Е.В., Недоступ А.В. и др. Случай болезниФабри глазами кардиолога и генетика. Кардиология 2009; 5: 54–58.


42. Shah J.S., Hughes D.A., Sachdev B. et al. Prevalence and clinical significanceof cardiac arrhythmia in Anderson-Fabry disease. Am. J. Cardiol. 2005; 96(6):842–846.


43. Sims K., Politei J., Banikazemi M., Lee P. Stroke in Fabry disease frequentlyoccurs before diagnosis and in the absence of other clinical events: naturalhistory data from the Fabry Registry. Stroke. 2009; 40(3): 788–794.


44. Rolfs A., Bottcher T., Zschiesche M. et al. Prevalence of Fabry diseasein patients with cryptogenic stroke: a prospective study. Lancet. 2005;366(9499): 1794–1796.


45. Vibert D., Blaser B., Ozdoba C., et al. Fabry’s disease: otoneurologic findingsin twelve members of one family. Ann. Otol. Rhinol. Laryngol. 2006; 115(6):412–418.


46. Germain D.P., Avan P., Chassaing A. et al. Patients affected with Fabry diseasehave an increased incidence of progressive hearing loss and sudden deafness:an investigation of twenty-two hemizygous male patients. BMC Med. Genet.2002; 3: 10.


47. Conti G., Sergi B. Auditory and vestibular findings in Fabry disease: a studyof hemizygous males and heterozygous females. Acta Paediatr. Suppl. 2003;92(443): 33–37.


48. Cimaz R., Guillaume S., Hilz M.J. et al. Awareness of Fabry disease amongrheumatologists – current status and perspectives. Clin. Rheumatol. 2010[Epub ahead of print].


49. Schaefer R.M., Tylki-Szymanska A., Hilz M.J. Enzyme replacement therapyfor Fabry disease: a systematic review of available evidence. Drugs 2009;69(16): 2179–2205.


50. ilcox W.R., Banikazemi M., Guffon N. et al. Long-term safety and efficacyof enzyme replacement therapy for Fabry disease. Am. J. Hum. Genet. 2007;75: 65–74.


51. Germain D.P., Waldek S., Banikazemi M., et al. Sustained, long-term renalstabilization after 54 moths of agalsidase β therapy in patients with Fabrydisease. J. Am. Soc. Nephrol. 2007; 18: 1547–1557.


52. Banikazemi M., Bultas J., Waldeck S. et al. Agalsidase-beta therapy foradvanced Fabry disease. A randomized trial. Ann. Intern. Med. 2007;146: 77–86.


53. Wraith J.E., Tylki-Szymanska A., Guffon N. et al. Safety and efficacyof enzyme replacement therapy with agalsidase beta: an international,open-label study in pediatric patients with Fabry disease. J. Pediatr. 2008;152: 563–570.


54. Watt T., Burlina A.P., Cazzorla C. et al. Agalsidase beta treatment is associatedwith improved quality of life in patients with Fabry disease: Findings from theFabry Registry. Genet Med. 2010 Sep 29. [Epub ahead of print].


55. Imbriaco M., Pisani A., Spinelli L. et al. Effects of enzyme-replacement therapyin patients with Anderson-Fabry disease: a prospective long-term cardiacmagnetic resonance imaging study. Heart. 2009; 95(13): 1103–1107.


56. Spinelli L., Pisani A., Sabbatini M. et al. Enzyme replacement therapy withagalsidase beta improves cardiac involvement in Fabrycs disease. Clin. Genet.2004; 66(2): 158–165.


57. Weidemann F., Niemann M., Breunig F. et al. Long-term effects of enzymereplacement therapy on Fabry cardiomyopathy: evidence for a better outcomewith early treatment. Circulation. 2009; 119(4): 524–529.


58. Tahir H., Jackson L.L., Warnock D.G. Antiproteinuric therapy and fabrynephropathy: sustained reduction of proteinuria in patients receiving enzymereplacement therapy with agalsidase-beta. J. Am. Soc. Nephrol. 2007; 18(9):2609–2617.


59. Ortiz A., Oliveira J.P., Wanner C. et al. Recommendations and guidelines forthe diagnosis and treatment of Fabry nephropathy in adults. Nat. Clin. Pract.Nephrol. 2008; 4(6): 327–336.


Об авторах / Для корреспонденции


Фомин В.В. – профессор кафедры терапии и профболезней медико-профилактического факультета, декан факультета довузовского образования ГОУ ВПО “Первый МГМУ имени И.М. Сеченова” Минздравсоцразвития РФ, д.м.н.
E-mail: fomin_vic@mail.ru;
Пулин А.А. – ассистент кафедры терапии и профболезней медико-профилактического факультета ГОУ ВПО “Первый МГМУ имени И.М. Сеченова” Минздравсоцразвития РФ, к.м.н.
E-mail: andereypulin@gmail.com;
Рамеев В.В. – ассистент кафедры терапии и профболезней медико-профилактического факультета, ведущий научный сотрудник отдела нефрологии Научно-исследовательского центра МПФ ГОУ ВПО “Первый МГМУ имени И.М. Сеченова” Минздравсоцразвития РФ, к.м.н.
E-mail: vilen.rameev@mtu-net.ru;
Седов В.П. – профессор кафедры лучевой диагностики и лучевой терапии лечебного факультета ГОУ ВПО “Первый МГМУ имени И.М. Сеченова” Минздравсоцразвития РФ, д.м.н.
E-mail: kafedra00@mail.ru;
Мешков А.Д. – клинический ординатор кафедры терапии и профболезней медико-профилактического факультета ГОУ ВПО “Первый МГМУ имени И.М. Сеченова” Минздравсоцразвития РФ.
E-mail: knvpb@mma.ru;
Рощупкина С.В. – заведующая нефрологическим отделением Клиники нефрологии, внутренних и профессиональных болезней им. Е.М. Тареева Университетской клинической больницы № 3 ГОУ ВПО “Первый МГМУ имени И.М. Сеченова” Минздравсоцразвития РФ.
E-mail: knvpb@mma.ru;
Панасюк В.В. – главный врач Университетской клинической больницы № 3 ГОУ ВПО “Первый МГМУ имени И.М. Сеченова” Минздравсоцразвития РФ, к.м.н.
E-mail: knvpb@mma.ru;
Козловская Л.В. – профессор кафедры терапии и профболезней медико-профилактического факультета ГОУ ВПО “Первый МГМУ имени И.М. Сеченова” Минздравсоцразвития РФ, д.м.н.
E-mail: knvpb@mma.ru;
Мухин Н.А. – академик РАМН, профессор, заведующий кафедрой терапии и профболезней медико-профилактического факультета, директор Клиники нефрологии, внутренних и профессиональных болезней им. Е.М. Тареева Университетской клинической больницы № 3 ГОУ ВПО “Первый МГМУ имени И.М. Сеченова” Минздравсоцразвития РФ, д.м.н.
E-mail: moukhin-nephro@yandex.ru


Похожие статьи


Бионика Медиа